|
Ferrer-Marín F, Bellosillo B, Martínez-Avilés L, Soler G, Carbonell P, Luengo-Gil G, Caparrós E, Torregrosa JM, Besses C, Vicente V. Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing. J Hematol Oncol. 2013 Sep 8;6:68. doi: 10.1186/1756-8722-6-68. PubMed PMID: 24011025; PubMed Central PMCID: PMC3847205.
AÑO: 2013; IF: 11.059
|
24011025
|
Ferrer-Marin F, Stanworth S, Josephson C, Sola-Visner M. Distinct differences in platelet production and function between neonates and adults: implications for platelet transfusion practice. Transfusion. 2013 Nov;53(11):2814-21; quiz 2813. doi: 10.1111/trf.12343. Review. PubMed PMID: 23889476.
AÑO: 2013; IF: 3.568
|
|
Hernández-Boluda JC, Pereira A, Cervantes F, Gómez M, Arellano-Rodrigo E, Alvarez-Larrán A, Ferrer-Marín F, Kerguelen A, Márquez JA, Antelo ML, Besses C; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN).. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. Ann Hematol. 2013 Jun;92(6):771-5. doi: 10.1007/s00277-013-1683-7. PubMed PMID: 23354997.
AÑO: 2013; IF: 2.396
|
|
Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, Angona A, Gómez M, Muiña B, Guillén H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012 Feb 9;119(6):1363-9. doi: 10.1182/blood-2011-10-387787. Epub 2011 Dec 12. PubMed PMID: 22160617.
AÑO: 2012; IF: 9.06
|
|
Ferrer-Marín F, Amigo ML, Vicente V. Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors. Clin Drug Investig. 2012 Jun 1;32(6):423-6. doi: 10.2165/11599850-000000000-00000. PubMed PMID: 22550963.
AÑO: 2012; IF: 1.915
|